Stroke prevention in atrial fibrillation

Netherlands Journal of Medicine

Volumn 64, Issue 2, 2006, Pages 31-33

  Verheugt, F W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Atrial fibrillation; Cardioversion; Stroke; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; IDRAPARINUX; IRBESARTAN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVERSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; INCIDENCE; MORTALITY; RHEUMATIC HEART DISEASE; RISK REDUCTION; SINUS RHYTHM; STROKE; THROMBOEMBOLISM;

ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; WARFARIN;

EID: 33344461871     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke. The Framingham study. Arch Intern Med 1987;147:1561-4.
2. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med 1987;317:669-74.
3. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-50.
4. SPAF-III Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-8.
5. Cannegieter SC, Rosenclaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
6. Brouwer MA, Verheugt FWA. Oral anticoagulants in acute coronary syndromes. Circulation 2002;105:1270-4.
7. Cromheecke ME, Levi M, Colly LP, et al. Oral anticoagulation self-management and management by a specialist clinic: a randomised crossover comparison. Lancet 2000;356:97-102.
8. Eriksson BI, Bergqvist D, Kälebo R et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
9. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom Y, et al. Oral ximelagatran for secondary prophylaxis after myocardial infiarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
10. Petersen P, Grind M, Adler J, et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II - a dose-guiding, tolerability and safety study. J Am Coll Cardiol 2002;41:1445-51.
11. SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: SPORTIF III trial. Lancet 2003;362:1691-8.
12. Halperin JL. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: SPORTIF V. JAMA 2005;293:690-8.
13. Wallentin L, Ezekowitz M, Simmers TA, et al. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: a dose finding trial with comparison to warfarin [abstract]. Eur Heart J 2005;26(suppl):482.
14. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation. BMJ 2002;325:1022-5.
15. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1825-33.
16. AFFIRM Investigators. A comparison of rate and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1834-40.